NETRF has funded $3.5 million in neuroendocrine tumor research grants to advance treatment options. The grants support innovative approaches to immunotherapy, pheochromocytoma and paraganglioma research, and lung NET studies.
Researchers funded by Neuroendocrine Tumor Research Foundation (NETRF) discover molecular information that can help predict the recurrence of non-functional pancreatic neuroendocrine tumors. The study identifies two new subtypes of pNETs, one with a high risk of recurrence and another with an excellent prognosis.
The Neuroendocrine Tumor Research Foundation (NETRF) has awarded $2.5 million in grants to support research into neuroendocrine cancers, including lung NETs. These grants will fund projects exploring various innovative therapies, such as CAR T-cell therapy and photodynamic therapy.
The Neuroendocrine Tumor Research Foundation (NETRF) has awarded six new research grants totaling $1.85 million to leading academic institutions worldwide. The funding aims to improve current treatments for neuroendocrine tumors, a rare and poorly understood cancer affecting hormone-producing cells.
The Neuroendocrine Tumor Research Foundation (NETRF) has awarded $4 million in grants to study neuroendocrine tumors, a widely misunderstood and misdiagnosed cancer type. Researchers will use genomic sequencing, gene editing, and bioengineering approaches to identify key vulnerabilities and develop personalized treatment options.
The NET Research Foundation has received a major gift to launch the most ambitious research effort ever undertaken to control and cure neuroendocrine cancers. The $15 million gift will support researchers dedicated to finding a cure for this rare disease, which affects over 100,000 Americans annually.